Next Article in Journal
Comprehensive Proteomic Analysis of Colon Cancer Tissue Revealed the Reason for the Worse Prognosis of Right-Sided Colon Cancer and Mucinous Colon Cancer at the Protein Level
Previous Article in Journal
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
Guidelines

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements

1
Department of Pharmacy, Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada
2
Departments of Medicine and Oncology, McGill University, Montreal, QC H3T 1E2, Canada
3
Princess Margaret Cancer Centre, Toronto, ON M5T 2M9, Canada
4
Department of Internal Medicine, Dermatology Division, CHU de Québec, Université Laval, Quebec City, QC G1Y 0A1, Canada
5
Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada
6
Department of Medical Oncology, BC Cancer, The University of British Columbia, Vancouver, BC V5Z 1M9, Canada
7
Department of Internal Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada
8
Department of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
*
Author to whom correspondence should be addressed.
Members of Canadian Working Group are listed in Acknowledgments.
Curr. Oncol. 2021, 28(5), 3537-3553; https://doi.org/10.3390/curroncol28050304
Received: 30 July 2021 / Revised: 7 September 2021 / Accepted: 8 September 2021 / Published: 14 September 2021
The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least 50% of treated patients. Without appropriate intervention, pyrexia syndrome has the potential to worsen and can result in hypotension secondary to dehydration and associated organ-related complications. Furthermore, premature treatment discontinuation may result in a reduction in progression-free and overall survival. Despite existing guidance, there is still a wide variety of therapeutic approaches suggested in the literature for both the definition and management of dabrafenib and trametinib-related pyrexia. This is reflected in the practice variation of its prevention and treatment within and between Canadian cancer centres. A Canadian working group was formed and consensus statements were constructed based on evidence and finalised through a two-round modified Delphi approach. The statements led to the development of a pyrexia treatment algorithm that can easily be applied in routine practice. The Canadian working group consensus statements serve to provide practical guidance for the management of dabrafenib and trametinib-related pyrexia, hopefully leading to reduced discontinuation rates, and ultimately improve patients’ quality of life and cancer-related outcomes. View Full-Text
Keywords: melanoma; pyrexia; dabrafenib; trametinib melanoma; pyrexia; dabrafenib; trametinib
Show Figures

Figure 1

MDPI and ACS Style

Thawer, A.; Miller, W.H., Jr.; Gregorio, N.; Claveau, J.; Rajagopal, S.; Savage, K.J.; Song, X.; Petrella, T.M.; on behalf of the Canadian Working Group. Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Curr. Oncol. 2021, 28, 3537-3553. https://doi.org/10.3390/curroncol28050304

AMA Style

Thawer A, Miller WH Jr., Gregorio N, Claveau J, Rajagopal S, Savage KJ, Song X, Petrella TM, on behalf of the Canadian Working Group. Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Current Oncology. 2021; 28(5):3537-3553. https://doi.org/10.3390/curroncol28050304

Chicago/Turabian Style

Thawer, Alia, Wilson H. Miller Jr., Nancy Gregorio, Joël Claveau, Sudha Rajagopal, Kerry J. Savage, Xinni Song, Teresa M. Petrella, and on behalf of the Canadian Working Group. 2021. "Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements" Current Oncology 28, no. 5: 3537-3553. https://doi.org/10.3390/curroncol28050304

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop